Non-muscle-invasive bladder cancers (NMIBC) represent a heterogeneous group of tumors with variable clinical outcomes. Multiple risk features are incorporated in predicting the risk of recurrence and progression to muscle-invasive bladder cancer (MIBC). Intravesical immunotherapy with Bacillus Calmette-Guerin (BCG) and chemotherapy are both considered adjuvant treatment options. However, it is challenging to define the optimum adjuvant therapy, particularly in intermediate-risk NMIBC cases. Considering the current BCG shortage, the risk-stratification tool for intermediate-risk patients is essential.